Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted fromin-vivo rat data?
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
In a drug discovery environment, reasonable go/no-go human in-vivo pharmacokinetic (PK) decisions must be made in a timely manner with a minimum amount of animal in-vivo or in-vitro data. We have investigated the accuracy of the in-vivo correlation between rat and human for the prediction of the total systemic clearance (CL), the volume of distribution at steady state (Vss), and the half-life (t1/2) using simple allometric scaling techniques. We have shown, using a large diverse set of drugs, that a fixed exponent allometric scaling approach can be used to predict human in-vivo PK parameters CL, Vss and t(1/2) solely from rat in-vivo PK data with acceptable accuracy for making go/no-go decisions in drug discovery. Human in-vivo PK predictions can be obtained using the simple allometric scaling relationships CL(Human) approximately = 40 CL(Rat) (L/hr), Vss(Human) approximately = 200 Vss(Rat) (L), and t1/2(Human) approximately = 4 t1/2(Rat) (hr). The average fold error for human CL predictions for N = 176 drugs was 2.25 with 79% of the drugs having a fold error less than 3. The average fold error for human Vss predictions for N = 144 drugs was 1.85 with 84% of the drugs having a fold error less than 3. The average fold error for human t1/2 predictions for N = 145 drugs was 2.05 with 76% of the drugs having a fold error less than 3. Using these simple allometric relationships, the sorting of drug candidates into a low/medium/high/very high human classification scheme was also possible from rat data. Since these simple allometric relationships between rat and human CL, Vss, and t1/2 are reasonably accurate, easy to remember and simple to calculate, these equations should be useful for making early go/no-go in-vivo human PK decisions for drug discovery candidates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They reported that single-species scaling, particularly when anchored to physiologically based corrections, can yield acceptable predictions for many small molecules.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [62]
Citations
Cites
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232 · cited 1×
“The prediction of human in-vivo hepatic clearance (CLH) has been studied using several different humanized in-vitro systems such as, hepatic microsomes (14, 15), heterologously expressed cytochrome P450 (CYPs) enzymes (16) and hepatocytes (17 - 19).”
BackgroundThe Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987 · cited 7×
“Simple allometric methods using three animal species are thought not to be sufficiently accurate in predicting human drug half-lives to be of practical value (13,24,31).”
BackgroundMethodInfluentialThe prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 3×
“Both methods are related to the standard allometric equation (25):”
BackgroundMethodPrediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479 · cited 1×
“, well-stirred, parallel tube, or dispersion) for converting in-vitro intrinsic metabolic clearances (CLint) into in-vivo CLH values has been shown to be important for the predictive outcome of low and highclearance drugs (20).”
BackgroundPharmaceutical Statistics: Practical and Clinical Applications.
Wallenstein, S., & Bolton, S. (1986) · Journal of the American Statistical Association · doi:10.2307/2289267 · Cited by 430
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Pharmaceutical Statistics: Practical and Clinical Applications
Kershner, R. (1985) · Technometrics · doi:10.1080/00401706.1985.10488086 · Cited by 283
Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats
Chiou, W. L., & Barve, A. (1998) · Pharmaceutical Research · doi:10.1023/a:1011981317451 · Cited by 257 · cited 2×
“This lack of correlation between rat and human oral bioavailabilities is speculated to be more likely due to factors such as drug formulation and metabolism differences than absorption factors, since literature data indicates that the in-vivo oral absorption in rats is a good early predictor of human oral absorption (…”
BackgroundMethodDesign of drugs involving the concepts and theories of drug metabolism and pharmacokinetics
Smith, D. A., Jones, B., & Walker, D. K. (1996) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199605)16:3<267::aid-med3>3.0.co;2-x · Cited by 239
Research works printed but not linked: 2
- Spasov, A. A.; Stepanov, A.V.; Smirnova, L. A.; Petrov, V. I.; Shabasheva, I. G. (2002). Pharmacokinetics of rhythmidazol upon single intravenous administration. Eksperimental’naya i Klinicheskaya Farmakologiya 65(3), 57–61.
- Vo_eh, S.; Schmidlin, O.; Taeschner, W. (1989). Pharmacokinetic drug Data. In: Clinical Pharmacokinetic Drug Data Handbook 1989. ADIS Press Limited, New Zealand, p. 1–38.
Cited by
Items 101–150 of 150
Dorel, R., Sun, D., Carruthers, N. I., Castanedo, G. M., Ung, P. M. U., Factor, D. C., Li, T., Baumann, H. M., Janota, D., Pang, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02396 · Cited by 5
Clinical relevance of predictive physiologically based pharmacokinetic methods
Thomas, S. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.7.725 · Cited by 5
“Prediction of in vivo clearance compared favourably with scaling from rat in vivo data (see Table 1 ) [9,10] .”
MethodResultBlass, B. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411508-8.00009-8 · Cited by 5
Moraes, B. K. S., Azeredo, F. J., Izoton, J. C., Amaral, M., Barreiro, E. J., Freddo, R. J., Costa, T. D., Lima, L. M., & Haas, S. E. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1405465 · Cited by 5
“Caldwell et al. (2004) proposed a classification in which Vdss, Cltot and t½ were considered low, medium, high or very high, aiming to provide simple human/ rat allometric scaling, as follows: CLHuman 40 CLRat (L/h), VdssHuman 200 VdssRat (L) and t½Human 4 t½Rat (h).”
Cytochrome P450: In Vitro Methods and Protocols
Yan, Z., & Caldwell, G. W. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1542-3_1 · Cited by 5
Ngo, L. T., Lee, C.-H., Han, N., Back, H., Rhee, S., Noh, K., Yun, H., Kang, W., & Chae, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051862 · Cited by 7
Recent advances in pharmacokinetic extrapolation from preclinical data to humans
Ward, K. W. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.4.583 · Cited by 5
Integrated Assessment of Drug Clearance and Cross‐Species Scalability
Beaumont, K. C., Gosset, J. R., & Keefer, C. E. (2014) · Wiley eBooks · doi:10.1002/9781118783344.ch14 · Cited by 5
Bollar, G. E., Shaffer, K. M., Keith, J. D., Oden, A. M., Dowell, A. E., Ryan, K. J., Acosta, E. P., Guimbellot, J. S., Kiedrowski, M. R., & Birket, S. E. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae185 · Cited by 4
Stamm, S. M., Wagner, R., Lang, D., Skerra, A., & Gebauer, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070967 · Cited by 8
Prediction of human drug clearance using a single-species, fixed-exponent allometric approach
Hu, T., & Chiu, S. J. (2009) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · Cited by 4
Galsgaard, K. D., Hartmann, B., ROSENKILDE, M. M., Holst, J. J., Gasbjerg, L. S., & Sørensen, C. M. (2025) · Physiological Reports · doi:10.14814/phy2.70699 · Cited by 3
“…is 27 min in humans, whereas the half-life of GLP-2(1–33) is 7 min (Hartmann, 2000), the half-life is presumably four times lower in rats (Caldwell et al., 2004), however, some GLP-2(3–33) might still be present during the final period of the experiment, which is in line with the…”
Oxycodone recycling: A novel hypothesis of opioid tolerance development in humans
Linares, Ó., Fudin, J., Schiesser, W. E., Linares, A. D., & Boston, R. C. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.06.006 · Cited by 3
“4 days), using the following allometric equation [18]:”
MethodYoshida, T. (2009) · Journal of Applied Toxicology · doi:10.1002/jat.1470 · Cited by 3
Dose Finding in Single Dose Studies by Allometric Scaling
Lu, Z., Kaspera, R., Naritomi, Y., & Wang, T. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_3 · Cited by 3
Thomas, S. (2010) · Alternatives to Laboratory Animals · doi:10.1177/026119291003801s16 · Cited by 3
“(5) Physiologically-based pharmacokinetic modelling 83”
Experimental Planning and Execution
Mullane, K., Curtis, M. J., & Williams, M. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804725-5.00002-1 · Cited by 3
Mallillin, M. C., Silva, D. A., Miller, N. A., Zhao, S., Salami, M., Löbenberg, R., & Davies, N. M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070824 · Cited by 2
“Caldwell et al. [62] examined whether human clearance, volume of distribution, and half-life can be predicted solely from in vivo rat data.”
Rodzaj, W., Wacławik, M., Jurewicz, J., & Wielgomas, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189025 · Cited by 2
“Firstly, FIP-hydroxy has only been found in rats so far [18,20], and both quantitative and qualitative differences in metabolism between rats and humans are widely reported in the literature [54–57].”
Sayed, R. M., Mahmoud, S. T., Mostafa, E. A., El-Ashrey, M. K., & Moffid, M. A. (2025) · Separation Science Plus · doi:10.1002/sscp.70009 · Cited by 2
Wong, C., Muguiro, D. H., Lavergne, S. N., Behling‐Kelly, E. L., & Goggs, R. A. N. (2018) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2018.08.006 · Cited by 2
Dose Finding in Single Dose Studies by Allometric Scaling
Lu, Z., Kaspera, R., Naritomi, Y., & Wang, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-56637-5_3-1 · Cited by 1
Umemori, Y., Handa, K., Yoshimura, S., & Kageyama, M. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03922-3 · Cited by 2
“Therefore, methods relying solely on rat PK data are frequently employed for CL prediction in early drug discovery [15].”
Yoshida, T. (2010) · Indoor Environment · doi:10.7879/siej.13.141 · Cited by 1
A gel-forming α-MSH analog promotes lasting melanogenesis
Chang, C. L., Cai, Z. P., & Hsu, S. Y. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176008 · Cited by 2
Zainal, H. (2016) · UCL Discovery (University College London) · Cited by 2
Whitley, M. J. (2017) · DukeSpace (Duke University) · Cited by 2
Predicting Human Pharmacokinetics
(2012) · Methods and principles in medicinal chemistry · doi:10.1002/9783527645763.ch9 · Cited by 1
Dose Finding in Single Dose Studies by Allometric Scaling
Pähler, T., & Maas, J. (2010) · Springer eBooks · doi:10.1007/978-3-540-89891-7_3
Clinical Dose Estimation Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation
Guan, L. (2012) · Wiley eBooks · doi:10.1002/9781118180778.ch6
Extrapolation from Animals to Human Beings and Translational Science
Curry, S. H., & PhD, R. W. (2010) · Wiley eBooks · doi:10.1002/9780470665190.ch15 · Cited by 1
Why Do We Need In Vivo Models in Drug Metabolism?
Beaumont, K. C. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm068
EFFECT OF OBESITY ON HEPATIC DRUG METABOLISM
Chiney, M. S. (2013) · University of Minnesota Digital Conservancy (University of Minnesota)
Human Pharmacokinetics Prediction
Chandasana, H. (2016) · Journal of Drug Metabolism & Toxicology · doi:10.4172/2157-7609.1000e138
“Over the years many improvements have been included in the allometric scaling approach for better prediction [12-15].”
BackgroundOnthank, D. C. (2006) · Digital WPI · Cited by 2
Holistic Assessment of Compound Properties—In Vitro to In Vivo Pharmacology
Baxter, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00016-5
Blass, B. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817214-8.00010-5
Hayton, W. L., & Hu, T. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse059
Empirical and Translational Pilots
Reynolds, P. S. (2023) · Wiley eBooks · doi:10.1002/9781119800002.ch6
Samanta, P. N., Das, S., Mandal, D., & Ojha, P. K. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11322-3
“Previously, Caldwell et al. (1998) [17] have explored fixed-exponent allometric scaling methods to predict human pharmacokinetic parameters (CL, Vss, and t ₁ / ₂ ) using rat in vivo data.”
Wang, H., Zhang, P., Barigye, S. J., Empfield, J. R., & Wesolowski, S. S. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2557178
Soliman, M., Mostafa, N. S., Mahmoud, S. T., El‐Gamil, D. S., Abdel‐Halim, M., & Fouad, M. M. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124888
MetaStab‐Analyzer: Classification and Regression Models for Metabolic Stability Prediction
Rudik, A. V., Stolbov, L. A., Lagunin, A. A., Filimonov, D., & Poroikov, V. (2026) · Molecular Informatics · doi:10.1002/minf.70018
“The obtained and processed data on metabolic stability serve as the foundation for the creation of computational predictive models, including those that take into account interspecies differences [5].”
Yu, C., Zhang, J., Guo, H. C., Liu, L., Ma, J., Zou, J., Xiao, Z., Li, Z., Luo, Y., & He, M. (2026) · Environmental Research · doi:10.1016/j.envres.2026.124826
Liu, F., Liu, Z., Fang, L., Huang, J.-J., Zhang, X.-H., Zhang, X.-Y., Ma, C., Shi, S.-R., Ji, H., Xin, J.-W., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1768989 · Cited by 1
“Notably, the pharmacokinetic parameters obtained from rats can be extrapolated to rabbits using formulas from the literatures (van Valkengoed et al., 2025; Greenblatt, 1985; Caldwell et al., 2004; Karalis et al., 2001).”
Chen, A., Baccei, C. S., Baccei, J., Broadhead, A. R., Lorrain, K. I., Poon, M. M., Roppe, J. R., Schrader, T. O., Stebbins, K. J., Valdez, L. J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01049
Sheriffdeen, M. M. (2014) · Summit (Simon Fraser University)
Metadata
- Authors
- Caldwell, G. W., Masucci, J. A., Yan, Z., & Hageman, W.
- Affiliations
- Janssen Research & Development (United States) (US)
- ORCID
- Yan, Zhengyin
- Venue
- European Journal of Drug Metabolism and Pharmacokinetics
- Published
- 2004-06
- Volume
- 29
- Issue
- 2
- Pages
- 133-143
- ISSN
- 0378-7966 (ISSN-L)
- 2107-0180
- OpenAlex
- W2019418677
- Cited by
- 148
- References
- 56
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 4 · 2023: 7 · 2022: 2 · 2021: 6 · 2020: 9 · 2019: 4 · 2018: 7 · 2017: 10 · 2016: 8 · 2015: 5 · 2014: 8 · 2013: 7 · 2012: 8
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Drug Metabolism and Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- allometric scaling, pharmacokinetic prediction, rat-to-human extrapolation, half-life, go/no-go decisions, drug discovery
- MeSH terms
- Algorithms, Animals, Half-Life, Humans, Pharmacokinetics, Predictive Value of Tests, Regression Analysis, Species Specificity, Drug Design, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.